What does Medicare's 2026 site‑neutral drug payment rule mean for employers?

Medicare’s 2026 rule equalizes payment rates for drug administration across hospital outpatient and physician office settings, cutting federal spending by $290 million in its first year. While CMS expects savings, most employers haven’t adopted similar site‑neutral models—missing potential savings of up to $58.2 billion annually from lower infusion and specialty drug costs.